Teva Pharmaceutical Industries Ltd. $TEVA is Menora Mivtachim Holdings LTD.’s 5th Largest Position

Menora Mivtachim Holdings LTD. increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,920,294 shares of the company’s stock after purchasing an additional 427,000 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 4.0% of Menora Mivtachim Holdings LTD.’s portfolio, making the stock its 5th biggest position. Menora Mivtachim Holdings LTD.’s holdings in Teva Pharmaceutical Industries were worth $786,190,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Howard Bailey Securities LLC lifted its position in Teva Pharmaceutical Industries by 3.5% in the third quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock valued at $292,000 after buying an additional 494 shares during the last quarter. ASR Vermogensbeheer N.V. increased its position in shares of Teva Pharmaceutical Industries by 1.6% during the third quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after acquiring an additional 515 shares during the last quarter. Retirement Planning Co of New England Inc. raised its stake in shares of Teva Pharmaceutical Industries by 1.8% in the 3rd quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock valued at $671,000 after acquiring an additional 588 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Teva Pharmaceutical Industries by 0.5% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 118,209 shares of the company’s stock valued at $1,981,000 after acquiring an additional 615 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 6.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 10,794 shares of the company’s stock worth $207,000 after acquiring an additional 624 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Brian Savage sold 1,127 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the sale, the insider directly owned 10,914 shares in the company, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares of the company’s stock, valued at approximately $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 948,499 shares of company stock valued at $30,897,071. Insiders own 0.49% of the company’s stock.

Analysts Set New Price Targets

TEVA has been the subject of a number of research analyst reports. Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Piper Sandler reissued an “overweight” rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Finally, Barclays lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Teva Pharmaceutical Industries Trading Down 3.7%

Shares of TEVA stock opened at $29.34 on Friday. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a 50 day moving average price of $32.96 and a 200 day moving average price of $26.55. The stock has a market capitalization of $33.73 billion, a P/E ratio of 24.45, a price-to-earnings-growth ratio of 10.20 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. During the same period in the prior year, the business earned $0.71 EPS. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.